FDA status (May 2026)<\/strong><\/td>\n| Approved<\/td>\n | Approved<\/td>\n | Investigational [5][6]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n [\/et_pb_text][et_pb_text _builder_version=”4.27.6″ _module_preset=”default” text_font=”–et_global_body_font||||||||” text_text_color=”#FFFFFF” text_line_height=”24px” global_colors_info=”{}”]<\/p>\n \n
\nSide Effect Profile in Trials<\/strong><\/span><\/h3>\n <\/p>\n \n Reported side effects across all three compounds are dominated by gastrointestinal events [3][4][10]. The published TRIUMPH-1 and TRIUMPH-4 data suggest discontinuation rates due to adverse events climb with dose, and that the 12 mg arm of retatrutide has shown the highest discontinuation figures of the three compounds at their respective top doses in published Phase 3 trials [2][10]. Investigators have suggested that this rate is partly explained by patients reaching weight loss thresholds at which they themselves chose to discontinue [10].<\/p>\n <\/p>\n<\/div>\n Section summary.<\/strong><\/span>\u00a0Across pivotal Phase 3 trials, mean weight loss has scaled with the number of receptors a compound engages: semaglutide (single agonist) at 14.9%, tirzepatide (dual agonist) at 22.5%, and retatrutide (triple agonist) at 28.3% over 80 weeks. Gastrointestinal events dominate the reported tolerability profile of all three.<\/div>\n<\/div>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row custom_padding_last_edited=”on|phone” _builder_version=”4.27.6″ _module_preset=”default” custom_margin=”60px||||false|false” custom_margin_tablet=”60px||||false|false” custom_margin_phone=”0px||||false|false” custom_margin_last_edited=”on|phone” custom_padding=”||0px||false|false” custom_padding_tablet=”||80px||false|false” custom_padding_phone=”0px||80px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.6″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Handling Retatrutide in a Research Setting” _builder_version=”4.27.6″ _module_preset=”default” title_level=”h2″ title_font=”–et_global_body_font|700|||||||” title_text_color=”#FFFFFF” title_font_size=”28px” title_line_height=”1.2em” width=”81%” custom_margin_tablet=”15px||||false|false” custom_margin_phone=”30px||||false|false” custom_margin_last_edited=”on|phone” locked=”off” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.6″ _module_preset=”default” text_font=”–et_global_body_font||||||||” text_text_color=”#FFFFFF” text_line_height=”24px” header_3_font_size=”20px” global_colors_info=”{}”]<\/p>\n \n This section describes the laboratory handling of retatrutide reference material as it is documented in published peptide research protocols. It is not, and is not intended as, instruction for human or animal administration.<\/div>\n Reconstitution with Bacteriostatic Water<\/span><\/strong><\/h3>\nLyophilized peptide reference standards are typically reconstituted with bacteriostatic water for laboratory analytical work [17]. Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which suppresses microbial growth in multi-draw research vials over the working life of the reference standard [17]. Sterile water is the alternative diluent where benzyl alcohol is incompatible with the downstream assay. Reconstitution is performed by directing the diluent down the inner wall of the vial rather than directly onto the peptide cake, followed by gentle swirling to dissolve [17]. Reconstituted material should be characterized analytically before it is used as a comparator in any further work.<\/div>\n Storage and Stability<\/span><\/strong><\/h3>\nLyophilized retatrutide reference standard is typically stored desiccated at \u201320 \u00b0C, protected from light, until use [17]. Reconstituted solutions are typically refrigerated at 2\u20138 \u00b0C and used within the stability window indicated on the Certificate of Analysis for that batch. Stability of reconstituted GLP-1-class peptides is product- and batch-specific; refer to the supplier’s stability data for the specific lot in hand [17].<\/div>\n Common Concentrations Used in Published Research<\/strong><\/span><\/h3>\n\n The concentrations used in published preclinical and analytical retatrutide research vary by application \u2014 chromatographic characterization, receptor binding assays, and pharmacokinetic studies each call for different working concentrations. The Phase 3 trial program tested 4 mg, 9 mg, and 12 mg per once-weekly subcutaneous dose in human participants [1][2], and analytical work is typically referenced to those clinical concentrations even though laboratory protocols use much lower working dilutions for in vitro analysis.<\/p>\n <\/p>\n<\/div>\n Section summary.<\/strong><\/span>\u00a0Laboratory handling of retatrutide reference material follows standard peptide-chemistry practice: bacteriostatic water reconstitution, \u201320 \u00b0C lyophilized storage, and analytical characterization against a Certificate of Analysis before use. None of the handling described constitutes instruction for human administration.<\/div>\n<\/div>\n[\/et_pb_text][et_pb_button button_url=”https:\/\/99puritypeptides.com\/?s=glp&et_pb_searchform_submit=et_search_proccess” button_text=”Shop Research-Grade GLP-1 Peptides” _builder_version=”4.27.6″ _module_preset=”default” custom_button=”on” button_border_radius=”7px” button_font=”|||on|||||” button_use_icon=”off” custom_padding=”14px|22px|14px|22px|true|true” locked=”off” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][\/et_pb_row][et_pb_row custom_padding_last_edited=”on|phone” _builder_version=”4.27.6″ _module_preset=”default” custom_margin=”60px||||false|false” custom_margin_tablet=”60px||||false|false” custom_margin_phone=”0px||||false|false” custom_margin_last_edited=”on|phone” custom_padding=”||0px||false|false” custom_padding_tablet=”||80px||false|false” custom_padding_phone=”0px||80px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.6″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Sourcing Research-Grade Retatrutide” _builder_version=”4.27.6″ _module_preset=”default” title_level=”h2″ title_font=”–et_global_body_font|700|||||||” title_text_color=”#FFFFFF” title_font_size=”28px” title_line_height=”1.2em” width=”81%” custom_margin_tablet=”15px||||false|false” custom_margin_phone=”30px||||false|false” custom_margin_last_edited=”on|phone” locked=”off” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.6″ _module_preset=”default” text_font=”–et_global_body_font||||||||” text_text_color=”#FFFFFF” text_line_height=”24px” header_3_font_size=”20px” global_colors_info=”{}”]<\/p>\n \n The retatrutide research-supply landscape in 2026 is shaped both by demand for the compound and by the FDA’s enforcement posture [5][14][15][16].<\/p>\n <\/p>\n<\/div>\n What “Research Use Only” Actually Means<\/strong><\/span><\/h3>\n\n “Research use only” is a regulatory and labeling designation, not a marketing description. Reference standards supplied under that designation are intended for analytical work, comparator use in research assays, and stability or impurity studies. They are not therapeutic products, do not bear dosing instructions, and are not lawful for administration to humans or animals [14][15].<\/p>\n <\/p>\n<\/div>\n Verifying Purity: CoA, HPLC, Mass Spectrometry<\/strong><\/span><\/h3>\n\n A Certificate of Analysis (CoA) is the supplier’s batch-specific documentation of identity, purity, and impurity profile for a reference standard. For peptides, the standard analytical methods are reversed-phase high-performance liquid chromatography to quantify purity (typically reported as area-percent) and mass spectrometry to confirm identity by molecular mass. A complete CoA for a research peptide will typically include: assigned batch number, peptide sequence and molecular weight, HPLC purity result, mass spectrometry confirmation, water content, peptide content by quantitative method, and storage and handling instructions.<\/p>\n <\/p>\n<\/div>\n Red Flags When Evaluating a Peptide Vendor<\/strong><\/span><\/h3>\n\n Suppliers whose labeling or website language implies human use, suggests therapeutic effects, or markets the compound by comparison to FDA-approved drugs were the focus of the FDA’s enforcement actions in 2025 and 2026 [5][14][15][16]. Other indicators worth weighing include the absence of a batch-specific CoA, the absence of third-party analytical verification, the absence of a documented U.S. shipping and warehousing chain, and pricing significantly below the analytical-cost floor of producing a research-grade peptide.<\/p>\n <\/p>\n<\/div>\n Section summary.<\/strong><\/span>\u00a0Sourcing research-grade retatrutide reasonably means buying material that is labeled and sold strictly as a reference standard, accompanied by a batch-specific Certificate of Analysis, with documented HPLC and mass spectrometry verification. Vendors whose marketing implies human use carry both legal and quality risk.<\/div>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row custom_padding_last_edited=”on|phone” _builder_version=”4.27.6″ _module_preset=”default” custom_margin=”60px||||false|false” custom_margin_tablet=”60px||||false|false” custom_margin_phone=”0px||||false|false” custom_margin_last_edited=”on|phone” custom_padding=”||0px||false|false” custom_padding_tablet=”||80px||false|false” custom_padding_phone=”0px||80px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.6″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”The Future of Triple-Agonist Peptide Research” _builder_version=”4.27.6″ _module_preset=”default” title_level=”h2″ title_font=”–et_global_body_font|700|||||||” title_text_color=”#FFFFFF” title_font_size=”28px” title_line_height=”1.2em” width=”81%” custom_margin_tablet=”15px||||false|false” custom_margin_phone=”30px||||false|false” custom_margin_last_edited=”on|phone” locked=”off” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.6″ _module_preset=”default” text_font=”–et_global_body_font||||||||” text_text_color=”#FFFFFF” text_line_height=”24px” header_3_font_size=”20px” global_colors_info=”{}”]<\/p>\n \n The trajectory of metabolic peptide research, viewed across the published literature, is toward broader receptor coverage in single molecules and toward combination protocols using complementary mechanisms [4][11].<\/div>\n \nCombination Compounds (CagriSema and others)<\/strong><\/span><\/h3>\nThe CagriSema program (cagrilintide combined with semaglutide) represents the combination-formulation approach to broadening mechanism: pairing two compounds with complementary mechanisms rather than building one larger molecule [4]. Investigators have noted that combination protocols offer dose-titration flexibility that single molecules do not.<\/div>\n Four-Receptor Compounds in Early Development<\/span><\/strong><\/h3>\n\n Earlier-stage research on four-receptor agonists \u2014 adding amylin receptor activity to GLP-1, GIP, and glucagon activity \u2014 has appeared in preclinical literature [4]. None has yet entered Phase 3, and triple agonism remains the most-watched class in current clinical-trial publication.<\/p>\n <\/p>\n<\/div>\n Section summary.<\/strong><\/span>\u00a0Retatrutide sits at the leading edge of a research trajectory toward broader receptor coverage in metabolic peptides. Combination formulations like CagriSema and earlier-stage four-receptor compounds illustrate the directions the field is moving next.<\/div>\n<\/div>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row custom_padding_last_edited=”on|phone” _builder_version=”4.27.6″ _module_preset=”default” custom_margin=”60px||||false|false” custom_margin_tablet=”60px||||false|false” custom_margin_phone=”0px||||false|false” custom_margin_last_edited=”on|phone” custom_padding=”||0px||false|false” custom_padding_tablet=”||80px||false|false” custom_padding_phone=”0px||80px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.6″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Key Takeaways” _builder_version=”4.27.6″ _module_preset=”default” title_level=”h2″ title_font=”–et_global_body_font|700|||||||” title_text_color=”#FFFFFF” title_font_size=”28px” title_line_height=”1.2em” width=”81%” custom_margin_tablet=”15px||||false|false” custom_margin_phone=”30px||||false|false” custom_margin_last_edited=”on|phone” locked=”off” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.6″ _module_preset=”default” text_font=”–et_global_body_font||||||||” text_text_color=”#FFFFFF” text_line_height=”24px” global_colors_info=”{}”]<\/p>\n \n \n \n – Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly, acting at GIP, GLP-1, and glucagon receptors [1][3].<\/p>\n <\/p>\n<\/div>\n \n – In the Phase 3 TRIUMPH-1 trial reported May 21, 2026, the 12 mg arm produced mean body-weight reduction of 28.3% at 80 weeks, with extension data reaching 30.3% at 104 weeks [1][2].<\/p>\n <\/p>\n<\/div>\n – Published Phase 3 weight-loss results for retatrutide exceed those reported for tirzepatide (22.5% in SURMOUNT-1) and semaglutide (14.9% in STEP-1) at comparable timepoints [1][2][9].<\/div>\n \n – Retatrutide is not FDA-approved and, under FDA guidance, cannot lawfully be used in compounding [5][6][14][15].<\/p>\n <\/p>\n<\/div>\n \n – The FDA issued more than 50 warning letters to GLP-1 vendors in September 2025, with several explicitly naming retatrutide; a follow-up round in March 2026 targeted telehealth platforms [5][14][16].<\/p>\n <\/p>\n<\/div>\n \n – A “research use only” label does not exempt a product from FDA requirements where the product is in fact marketed for human use [14][15].<\/p>\n <\/p>\n<\/div>\n – Research-grade retatrutide reference standards are handled by standard peptide-chemistry protocols: bacteriostatic water reconstitution, lyophilized \u201320 \u00b0C storage, and CoA-supported analytical verification.<\/div>\n<\/div>\n<\/div>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row custom_padding_last_edited=”on|phone” _builder_version=”4.27.6″ _module_preset=”default” background_color=”#000000″ custom_margin=”60px||||false|false” custom_padding=”60px|40px|60px|40px|true|true” custom_padding_tablet=”||80px||false|false” custom_padding_phone=”||80px||false|false” border_radii=”on|20px|20px|20px|20px” border_width_all=”1px” border_color_all=”#1E5D68″ global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.6″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Start Your Research Today” _builder_version=”4.27.6″ _module_preset=”default” title_level=”h2″ title_font=”–et_global_body_font|700|||||||” title_text_align=”center” title_text_color=”#FFFFFF” title_font_size=”28px” title_line_height=”1.2em” width=”100%” custom_margin_tablet=”15px||||false|false” custom_margin_phone=”30px||||false|false” custom_margin_last_edited=”on|phone” locked=”off” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.6″ _module_preset=”default” text_font=”–et_global_body_font||||||||” text_text_color=”#FFFFFF” text_line_height=”24px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n \n Every retatrutide vial we supply ships with full third-party Certificate of Analysis documentation \u2014 so your research begins with verified purity, not assumptions.<\/div>\n<\/div>\n [\/et_pb_text][et_pb_button button_url=”\/shop” button_text=”View All Research Peptides” button_alignment=”center” _builder_version=”4.27.6″ _module_preset=”default” custom_button=”on” button_text_size=”16px” button_border_radius=”8px” button_font=”|600||on|||||” custom_margin=”30px||||false|false” custom_padding=”15px|20px|15px|20px|true|true” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|tablet” _builder_version=”4.27.6″ _module_preset=”default” background_color=”#0a0202″ background_enable_image=”off” background_position=”center_right” custom_padding=”||||true|false” custom_padding_tablet=”||||false|false” custom_padding_phone=”||||true|false” custom_css_free_form=”@media (max-width: 1024px) and (min-width: 981px){|| selector {|| padding: 60px 0px 70px !important; ||}||}” locked=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.6″ _module_preset=”default” custom_padding=”0px||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Questions” _builder_version=”4.27.5″ _module_preset=”default” title_level=”h2″ title_font=”Montserrat|700|||||||” title_text_align=”center” title_text_color=”#ffffff” title_font_size=”32px” title_line_height=”42px” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.6″ _module_preset=”default” text_font=”Montserrat||||||||” text_text_color=”#fafafa” text_line_height=”26px” text_orientation=”center” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n Frequently Asked Questions (FAQs) About Retatrutide<\/b><\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row custom_padding_last_edited=”on|tablet” _builder_version=”4.27.5″ _module_preset=”default” width=”60%” width_tablet=”90%” width_phone=”90%” width_last_edited=”on|tablet” custom_margin=”30px||||false|false” custom_margin_tablet=”20px||||false|false” custom_margin_phone=”20px||||false|false” custom_margin_last_edited=”on|phone” custom_padding_tablet=”0px||||false|false” custom_padding_phone=”0px||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”][et_pb_accordion toggle_icon=”L||divi||400″ _builder_version=”4.27.6″ _module_preset=”default” border_radii=”on|8px|8px|8px|8px” global_colors_info=”{}”][et_pb_accordion_item title=”What is retatrutide?” open=”on” open_toggle_text_color=”#fafafa” open_toggle_background_color=”RGBA(255,255,255,0)” closed_toggle_text_color=”#fafafa” closed_toggle_background_color=”RGBA(255,255,255,0)” icon_color=”#fafafa” toggle_icon=”L||divi||400″ use_icon_font_size=”on” icon_font_size=”20px” _builder_version=”4.27.6″ _module_preset=”default” body_font=”Montserrat||||||||” body_text_color=”#fafafa” body_font_size=”14px” body_line_height=”24px” custom_padding=”25px||25px||true|false” global_colors_info=”{}” toggle_text_color=”#fafafa” toggle_level=”h3″ toggle_font=”Montserrat|700|||||||” toggle_font_size=”18px” toggle_line_height=”100%” closed_toggle_font=”Montserrat|700|||||||” closed_toggle_font_size=”18px” closed_toggle_line_height=”100%”]<\/p>\n \n \n Retatrutide is an investigational peptide developed by Eli Lilly under the code LY3437943. It is a synthetic 39-amino-acid molecule that activates three metabolic receptors \u2014 GIP, GLP-1, and glucagon \u2014 through a single compound. It has not been approved by any regulatory authority and is being evaluated in Phase 3 clinical trials [1][3].<\/div>\n<\/div>\n<\/div>\n [\/et_pb_accordion_item][et_pb_accordion_item title=”What does %22reta%22 mean in peptide forums?” open_toggle_text_color=”#fafafa” open_toggle_background_color=”RGBA(255,255,255,0)” closed_toggle_text_color=”#fafafa” closed_toggle_background_color=”RGBA(255,255,255,0)” icon_color=”#fafafa” toggle_icon=”L||divi||400″ use_icon_font_size=”on” icon_font_size=”20px” _builder_version=”4.27.6″ _module_preset=”default” body_font=”Montserrat||||||||” body_text_color=”#fafafa” body_font_size=”14px” body_line_height=”24px” custom_padding=”25px||25px||true|false” global_colors_info=”{}” toggle_text_color=”#fafafa” toggle_level=”h3″ toggle_font=”Montserrat|700|||||||” toggle_font_size=”18px” toggle_line_height=”100%” closed_toggle_font=”Montserrat|700|||||||” closed_toggle_font_size=”18px” closed_toggle_line_height=”100%” open=”off”]<\/p>\n \n \n “Reta” is the colloquial shorthand for retatrutide used widely on forums, social media, and in search queries. The same naming pattern appears for tirzepatide (“tirz”) and semaglutide (“sema”). It refers to the same investigational compound discussed in the published clinical literature.<\/div>\n<\/div>\n<\/div>\n [\/et_pb_accordion_item][et_pb_accordion_item title=”What is the chemical structure of retatrutide?” open_toggle_text_color=”#fafafa” open_toggle_background_color=”RGBA(255,255,255,0)” closed_toggle_text_color=”#fafafa” closed_toggle_background_color=”RGBA(255,255,255,0)” icon_color=”#fafafa” toggle_icon=”L||divi||400″ use_icon_font_size=”on” icon_font_size=”20px” _builder_version=”4.27.6″ _module_preset=”default” body_font=”Montserrat||||||||” body_text_color=”#fafafa” body_font_size=”14px” body_line_height=”24px” custom_padding=”25px||25px||true|false” global_colors_info=”{}” toggle_text_color=”#fafafa” toggle_level=”h3″ toggle_font=”Montserrat|700|||||||” toggle_font_size=”18px” toggle_line_height=”100%” closed_toggle_font=”Montserrat|700|||||||” closed_toggle_font_size=”18px” closed_toggle_line_height=”100%” open=”off”]<\/p>\n \n \n Retatrutide is a 39-amino-acid peptide containing several non-natural residues \u2014 including 2-aminoisobutyric acid and an \u03b1-methyl-leucine \u2014 along with a serinamide C-terminal modification and a fatty acid attachment that supports a once-weekly dosing interval in trials. The complete sequence is documented in published technical references [3].<\/div>\n<\/div>\n<\/div>\n [\/et_pb_accordion_item][et_pb_accordion_item title=”Who developed retatrutide?” open_toggle_text_color=”#fafafa” open_toggle_background_color=”RGBA(255,255,255,0)” closed_toggle_text_color=”#fafafa” closed_toggle_background_color=”RGBA(255,255,255,0)” icon_color=”#fafafa” toggle_icon=”L||divi||400″ use_icon_font_size=”on” icon_font_size=”20px” _builder_version=”4.27.6″ _module_preset=”default” body_font=”Montserrat||||||||” body_text_color=”#fafafa” body_font_size=”14px” body_line_height=”24px” custom_padding=”25px||25px||true|false” global_colors_info=”{}” toggle_text_color=”#fafafa” toggle_level=”h3″ toggle_font=”Montserrat|700|||||||” toggle_font_size=”18px” toggle_line_height=”100%” closed_toggle_font=”Montserrat|700|||||||” closed_toggle_font_size=”18px” closed_toggle_line_height=”100%” open=”off”]<\/p>\n \n \n Retatrutide was developed by Eli Lilly and Company, which retains the investigational designation LY3437943 for the molecule. Eli Lilly is currently running the TRIUMPH Phase 3 program for retatrutide in obesity and the TRANSCEND-T2D Phase 3 program in type 2 diabetes [1][3][8].<\/div>\n<\/div>\n<\/div>\n [\/et_pb_accordion_item][et_pb_accordion_item title=”How does retatrutide work?” open_toggle_text_color=”#fafafa” open_toggle_background_color=”RGBA(255,255,255,0)” closed_toggle_text_color=”#fafafa” closed_toggle_background_color=”RGBA(255,255,255,0)” icon_color=”#fafafa” toggle_icon=”L||divi||400″ use_icon_font_size=”on” icon_font_size=”20px” _builder_version=”4.27.6″ _module_preset=”default” body_font=”Montserrat||||||||” body_text_color=”#fafafa” body_font_size=”14px” body_line_height=”24px” custom_padding=”25px||25px||true|false” global_colors_info=”{}” toggle_text_color=”#fafafa” toggle_level=”h3″ toggle_font=”Montserrat|700|||||||” toggle_font_size=”18px” toggle_line_height=”100%” closed_toggle_font=”Montserrat|700|||||||” closed_toggle_font_size=”18px” closed_toggle_line_height=”100%” open=”off”]<\/p>\n \n \n Retatrutide binds to three receptors that regulate human energy metabolism: the GLP-1 receptor (appetite, insulin secretion, gastric emptying), the GIP receptor (insulin response, adipose handling), and the glucagon receptor (energy expenditure, hepatic lipid handling). Triple activation is the mechanism distinguishing it from earlier GLP-1-class compounds [3][4].<\/div>\n<\/div>\n<\/div>\n [\/et_pb_accordion_item][et_pb_accordion_item title=”What is a triple agonist peptide?” open_toggle_text_color=”#fafafa” open_toggle_background_color=”RGBA(255,255,255,0)” closed_toggle_text_color=”#fafafa” closed_toggle_background_color=”RGBA(255,255,255,0)” icon_color=”#fafafa” toggle_icon=”L||divi||400″ use_icon_font_size=”on” icon_font_size=”20px” _builder_version=”4.27.6″ _module_preset=”default” body_font=”Montserrat||||||||” body_text_color=”#fafafa” body_font_size=”14px” body_line_height=”24px” custom_padding=”25px||25px||true|false” global_colors_info=”{}” toggle_text_color=”#fafafa” toggle_level=”h3″ toggle_font=”Montserrat|700|||||||” toggle_font_size=”18px” toggle_line_height=”100%” closed_toggle_font=”Montserrat|700|||||||” closed_toggle_font_size=”18px” closed_toggle_line_height=”100%” open=”off”]<\/p>\n \n \n A triple agonist peptide is a single molecule that activates three different receptors at the same time. Retatrutide is the first triple hormone receptor agonist (GIP, GLP-1, glucagon) to reach Phase 3 clinical trials. Earlier classes activated one receptor (semaglutide) or two receptors (tirzepatide) [3][4].<\/div>\n<\/div>\n<\/div>\n [\/et_pb_accordion_item][et_pb_accordion_item title=”How is retatrutide different from tirzepatide?” open_toggle_text_color=”#fafafa” open_toggle_background_color=”RGBA(255,255,255,0)” closed_toggle_text_color=”#fafafa” closed_toggle_background_color=”RGBA(255,255,255,0)” icon_color=”#fafafa” toggle_icon=”L||divi||400″ use_icon_font_size=”on” icon_font_size=”20px” _builder_version=”4.27.6″ _module_preset=”default” body_font=”Montserrat||||||||” body_text_color=”#fafafa” body_font_size=”14px” body_line_height=”24px” custom_padding=”25px||25px||true|false” global_colors_info=”{}” toggle_text_color=”#fafafa” toggle_level=”h3″ toggle_font=”Montserrat|700|||||||” toggle_font_size=”18px” toggle_line_height=”100%” closed_toggle_font=”Montserrat|700|||||||” closed_toggle_font_size=”18px” closed_toggle_line_height=”100%” open=”off”]<\/p>\n \n \n Tirzepatide is a dual agonist acting on GLP-1 and GIP receptors. Retatrutide adds glucagon receptor activation, making it a triple agonist. In published Phase 3 trials, the mean weight loss reported for retatrutide at 80 weeks (28.3%) exceeded the mean reported for tirzepatide in SURMOUNT-1 at 72 weeks (22.5%) [1][2][9].<\/div>\n<\/div>\n<\/div>\n [\/et_pb_accordion_item][et_pb_accordion_item title=”How is retatrutide different from semaglutide (Ozempic \/ Wegovy)?” open_toggle_text_color=”#fafafa” open_toggle_background_color=”RGBA(255,255,255,0)” closed_toggle_text_color=”#fafafa” closed_toggle_background_color=”RGBA(255,255,255,0)” icon_color=”#fafafa” toggle_icon=”L||divi||400″ use_icon_font_size=”on” icon_font_size=”20px” _builder_version=”4.27.6″ _module_preset=”default” body_font=”Montserrat||||||||” body_text_color=”#fafafa” body_font_size=”14px” body_line_height=”24px” custom_padding=”25px||25px||true|false” global_colors_info=”{}” toggle_text_color=”#fafafa” toggle_level=”h3″ toggle_font=”Montserrat|700|||||||” toggle_font_size=”18px” toggle_line_height=”100%” closed_toggle_font=”Montserrat|700|||||||” closed_toggle_font_size=”18px” closed_toggle_line_height=”100%” open=”off”]<\/p>\n \n Semaglutide is a single-receptor agonist acting only on GLP-1. Retatrutide is a triple agonist acting on GLP-1, GIP, and glucagon receptors. The published Phase 3 mean weight reduction for retatrutide (28.3%) is nearly double the figure reported for semaglutide in STEP-1 (14.9%) over comparable trial durations [1][2][9].<\/div>\n<\/div>\n [\/et_pb_accordion_item][et_pb_accordion_item title=”Is retatrutide FDA-approved?” open_toggle_text_color=”#fafafa” open_toggle_background_color=”RGBA(255,255,255,0)” closed_toggle_text_color=”#fafafa” closed_toggle_background_color=”RGBA(255,255,255,0)” icon_color=”#fafafa” toggle_icon=”L||divi||400″ use_icon_font_size=”on” icon_font_size=”20px” _builder_version=”4.27.6″ _module_preset=”default” body_font=”Montserrat||||||||” body_text_color=”#fafafa” body_font_size=”14px” body_line_height=”24px” custom_padding=”25px||25px||true|false” global_colors_info=”{}” toggle_text_color=”#fafafa” toggle_level=”h3″ toggle_font=”Montserrat|700|||||||” toggle_font_size=”18px” toggle_line_height=”100%” closed_toggle_font=”Montserrat|700|||||||” closed_toggle_font_size=”18px” closed_toggle_line_height=”100%” open=”off”]<\/p>\n \n \n \n No. As of May 2026, retatrutide has not been approved by the FDA for any indication. It is an investigational drug in active Phase 3 clinical trials. The FDA has explicitly stated that retatrutide cannot be used in compounding under U.S. federal law [5][6][14][15].<\/div>\n<\/div>\n<\/div>\n<\/div>\n [\/et_pb_accordion_item][et_pb_accordion_item title=”When is retatrutide expected to be FDA-approved?” open_toggle_text_color=”#fafafa” open_toggle_background_color=”RGBA(255,255,255,0)” closed_toggle_text_color=”#fafafa” closed_toggle_background_color=”RGBA(255,255,255,0)” icon_color=”#fafafa” toggle_icon=”L||divi||400″ use_icon_font_size=”on” icon_font_size=”20px” _builder_version=”4.27.6″ _module_preset=”default” body_font=”Montserrat||||||||” body_text_color=”#fafafa” body_font_size=”14px” body_line_height=”24px” custom_padding=”25px||25px||true|false” global_colors_info=”{}” toggle_text_color=”#fafafa” toggle_level=”h3″ toggle_font=”Montserrat|700|||||||” toggle_font_size=”18px” toggle_line_height=”100%” closed_toggle_font=”Montserrat|700|||||||” closed_toggle_font_size=”18px” closed_toggle_line_height=”100%” open=”off”]<\/p>\n\n\n \n \n The May 21, 2026 TRIUMPH-1 readout was the first pivotal Phase 3 weight-loss result for retatrutide. Additional Phase 3 readouts are expected through 2026, with analyst commentary pointing to an Eli Lilly NDA filing in late 2026 at the earliest and a U.S. approval not anticipated before 2027 [1][13].<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n [\/et_pb_accordion_item][et_pb_accordion_item title=”What were the Phase 3 TRIUMPH-1 trial results?” open_toggle_text_color=”#fafafa” open_toggle_background_color=”RGBA(255,255,255,0)” closed_toggle_text_color=”#fafafa” closed_toggle_background_color=”RGBA(255,255,255,0)” icon_color=”#fafafa” toggle_icon=”L||divi||400″ use_icon_font_size=”on” icon_font_size=”20px” _builder_version=”4.27.6″ _module_preset=”default” body_font=”Montserrat||||||||” body_text_color=”#fafafa” body_font_size=”14px” body_line_height=”24px” custom_padding=”25px||25px||true|false” global_colors_info=”{}” toggle_text_color=”#fafafa” toggle_level=”h3″ toggle_font=”Montserrat|700|||||||” toggle_font_size=”18px” toggle_line_height=”100%” closed_toggle_font=”Montserrat|700|||||||” closed_toggle_font_size=”18px” closed_toggle_line_height=”100%” open=”off”]<\/p>\n\n\n \n \n TRIUMPH-1 reported mean body-weight reduction of 19.0%, 25.9%, and 28.3% on the 4 mg, 9 mg, and 12 mg arms respectively, compared with 2.2% on placebo over 80 weeks. In a blinded extension among participants with baseline BMI \u226535, mean weight loss reached 30.3% at 104 weeks [1][2].<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n [\/et_pb_accordion_item][et_pb_accordion_item title=”What conditions is retatrutide being studied for besides obesity?” open_toggle_text_color=”#fafafa” open_toggle_background_color=”RGBA(255,255,255,0)” closed_toggle_text_color=”#fafafa” closed_toggle_background_color=”RGBA(255,255,255,0)” icon_color=”#fafafa” toggle_icon=”L||divi||400″ use_icon_font_size=”on” icon_font_size=”20px” _builder_version=”4.27.6″ _module_preset=”default” body_font=”Montserrat||||||||” body_text_color=”#fafafa” body_font_size=”14px” body_line_height=”24px” custom_padding=”25px||25px||true|false” global_colors_info=”{}” toggle_text_color=”#fafafa” toggle_level=”h3″ toggle_font=”Montserrat|700|||||||” toggle_font_size=”18px” toggle_line_height=”100%” closed_toggle_font=”Montserrat|700|||||||” closed_toggle_font_size=”18px” closed_toggle_line_height=”100%” open=”off”]<\/p>\n\n\n \n \n Retatrutide is in Phase 3 trials for type 2 diabetes (TRANSCEND-T2D program), obstructive sleep apnea, metabolic dysfunction-associated steatotic liver disease, chronic kidney disease in patients with type 2 diabetes, knee osteoarthritis, and cardiovascular outcomes [1][8][10][11].<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n [\/et_pb_accordion_item][et_pb_accordion_item title=”What adverse events have been reported in retatrutide clinical trials?” open_toggle_text_color=”#fafafa” open_toggle_background_color=”RGBA(255,255,255,0)” closed_toggle_text_color=”#fafafa” closed_toggle_background_color=”RGBA(255,255,255,0)” icon_color=”#fafafa” toggle_icon=”L||divi||400″ use_icon_font_size=”on” icon_font_size=”20px” _builder_version=”4.27.6″ _module_preset=”default” body_font=”Montserrat||||||||” body_text_color=”#fafafa” body_font_size=”14px” body_line_height=”24px” custom_padding=”25px||25px||true|false” global_colors_info=”{}” toggle_text_color=”#fafafa” toggle_level=”h3″ toggle_font=”Montserrat|700|||||||” toggle_font_size=”18px” toggle_line_height=”100%” closed_toggle_font=”Montserrat|700|||||||” closed_toggle_font_size=”18px” closed_toggle_line_height=”100%” open=”off”]<\/p>\n
|